JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial.
BACKGROUND
Pre-diabetes is a growing health concern where a large percentage of these patients develop full type 2 diabetes. Effective interventions on pre-diabetes can prevent or delay the occurrence or development of diabetes. Pharmacodynamics and pre-clinical of JinQi-Jiangtang tablets (JQJT) suggest that it could be benefit for pre-diabetes.


METHODS
Randomized controlled trial (RCT) is implemented in this study. The study term is 24 months (12 months for intervention and 12 months for follow up). Participants are recruited from four cities of China: Beijing, Tianjin, Xi'an and Nanning. Four hundred participants are randomized to treatment group (JQJT tablets) and control group (Placebo); two hundred participants each. People being included in this study must have been diagnosed as pre-diabetes via western medicine criteria and traditional Chinese medicine (TCM) criteria. The end-point indexes include: incidence of diabetes mellitus and reversion rate. Primary outcome indexes include: oral glucose tolerance test; insulin releasing test; glycosylated hemoglobin (HA1c). Secondary outcome indexes include: score of the Short Form 36 Health Survey Questionnaire (SF-36); score of TCM symptoms; blood lipid test. Indexes of safety include: general medical examination; blood and urine regular test; electrocardiogram (ECG), liver function (ALT) and renal function (BUN, Creatinine) test; record of adverse event, such as headache, faint, etc. Qualitative control will be implemented and a number of standard operating processes (SOPs) will be formed throughout the study: laboratory quality control measures; compliance control for researchers and participants; researcher training before study; supervision; investigational drug management and others.


CONCLUSIONS
The aim of this study is to evaluate the effectiveness and safety of JinQi JiangTang (JQJT) tablets for the treatment of patients with pre-diabetes.


BACKGROUND
Chinese clinical trials register ChiCTR-TRC-00000401.
Cao
Hongbo
H
Clinical Assessment Institute, Tianjin University of TCM, Yuquan street, Tianjin, 300193, China.
Ren
Ming
M
Guo
Liping
L
Shang
Hongcai
H
Zhang
Junhua
J
Song
Yuzhen
Y
Wang
Hui
H
Wang
Baohe
B
Li
Xiantao
X
Hu
Jing
J
Wang
Xuemei
X
Wang
Dehui
D
Chen
Jianzong
J
Li
Shuanglei
S
Chen
Liming
L
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002681:China; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D018450:Disease Progression; D004311:Double-Blind Method; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010330:Patents as Topic; D011236:Prediabetic State / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D012107:Research Design; D013607:Tablets; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; D004365:Drugs, Chinese Herbal; D007004:Hypoglycemic Agents; D013607:Tablets; C527173:jinqi jiantang